ArticleIntestinal research2017
Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers.
Article in Intestinal research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Olmesartan induced gastritis and enteropathy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- The histological spectrum of ARB-induced gastritis.Histopathology · 2022Article
- A Case of Sprue-like Enteropathy Associated With Valsartan and Irbesartan.Journal of neurogastroenterology and motility · 2022Article
- Telmisartan-induced sprue-like enteropathy: a case report.European journal of hospital pharmacy : science and practice · 2020Article
- Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.Wiener klinische Wochenschrift · 2019Review
- A simple treatment for a potentially life-threatening cause of malabsorption.Internal and emergency medicine · 2019Article
- Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review.Gastroenterology report · 2019Review
- Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy.Pharmacoepidemiology and drug safety · 2018Observational
- A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.Journal of clinical medicine research · 2017Article
- Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have identified sprue-like illness associated with the use of the antihypertensive agent olmesartan medoxomil. However, whether this condition is specific to the use of olmesartan or is associated with the use of drugs belonging to the class of "sartans" remains to be clarified. A 45-year-old woman with chronic kidney disease along with hypothyroidism and hypertension presented with chronic diarrhea and significant weight loss. Endoscopy of the upper gastrointestinal tract showed scalloping and grooving of the duodenum, and histopathological examination showed subtotal villous atrophy. She was on telmisartan for hypertension, which was discontinued. Subsequently, diarrhea ameliorated dramatically, and she regained weight. To our knowledge, this is the first study to report telmisartan-associated sprue-like enteropathy. Further, we have reviewed the cases of patients with sprue-like enteropathy caused by valsartan, irbesartan, and eprosartan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.